KBL Merger Corp. IV (NASDAQ: KBLM or the “Company”), a special purpose acquisition company (SPAC) that previously announced the signing of a definitive agreement to acquire 180 Life Sciences Corp. (“180 Life Sciences”), today announced that 180 Sciences Corp. continues to expand their robust IP portfolio.
180 Life Sciences Corp. is an applicant and licensee of a broad and growing patent portfolio for three major drug platforms in the areas of inflammation, fibrosis and pain. The patent portfolio covers 14 patent families with 42 patents issued and 32 pending in several important jurisdictions, including the United States, Canada, Europe, Australia, Japan and China.
On June 3rd, 2020, the EU Patent and Trademark Office granted patent number 2547363 “Methods of Prevention or Treatment of Triggered Inflammatory Reactions Using TNF Alpha Antagonist”, which is part of a family of patents the Company has in its extensive patent portfolio.
Other recent filings and grants include:
- Granted: January 14th, 2020 Chinese patent ZL201580020978.7 for SCA: CYCLOHEXENYL COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES
- FILED: April 22nd, 2020 US patent application 62/704,121 SCA: BIOACTIVE PHENOLATE IONIC COMPLEXES
- GRANTED: June 2nd, 2020 US patent 10669334 TREATMENT FOR DUPUYTREN’S DISEASE
- FILED: September 1st, 2020 Hong Kong patent application 62020001194.3 for METHOD OF TREATING SYSTEMIC FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY
The Company’s patent portfolio is made up of both its own IP and exclusive worldwide licenses, with, Oxford University Innovation Limited, The Kennedy Trust for Rheumatology Research University of Oxford, Stanford University, and the Hebrew University
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“The issuance of our European patents significantly strengthens the IP portfolio governing our lead program,” said Dr. James Woody, 180 Life Sciences Corp’s CEO, “We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies. Having this most recent patent awarded in the EU is important as it provides validation in the 12 largest countries in the EU, including the UK, and provides the platform to be able to expand clinical trials, commercialization and partnering efforts throughout Europe. We look forward to achieving additional milestones by the end of 2020.”
Source: Biospace